NASDAQ · IOVA
Healthcare · Biotechnology
$9.87
Up+$0.15 (+1.52%)
Updated Sep 17, 2026, 8:44 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
IOVA closed at $10.02 after 20 trading sessions, up 11.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $10.25 | $10.98 | $9.985 | $10.02 | 24.2M |
| Sep 16, 2026 | $9.45 | $9.925 | $9.435 | $9.87 | 19.69M |
| Sep 15, 2026 | $9.21 | $9.38 | $8.98 | $9.36 | 11.09M |
| Sep 14, 2026 | $8.56 | $9.41 | $8.54 | $9.26 | 21.04M |
| Sep 11, 2026 | $8.25 | $8.695 | $8.075 | $8.60 | 12.39M |
| Sep 10, 2026 | $8.32 | $8.4199 | $8.04 | $8.14 | 10.57M |
| Sep 9, 2026 | $8.655 | $8.73 | $8.32 | $8.43 | 11.94M |
| Sep 8, 2026 | $8.69 | $8.91 | $8.48 | $8.70 | 9.54M |
| Sep 4, 2026 | $8.74 | $8.90 | $8.635 | $8.79 | 8.08M |
| Sep 3, 2026 | $8.65 | $8.7897 | $8.55 | $8.70 | 14.64M |
| Sep 2, 2026 | $8.31 | $8.69 | $8.295 | $8.62 | 12.39M |
| Sep 1, 2026 | $8.02 | $8.29 | $7.97 | $8.28 | 6.76M |
| Aug 31, 2026 | $7.945 | $8.17 | $7.66 | $8.17 | 12.13M |
| Aug 28, 2026 | $8.20 | $8.35 | $7.97 | $8.01 | 7.69M |
| Aug 27, 2026 | $8.08 | $8.3186 | $7.95 | $8.26 | 7.44M |
| Aug 26, 2026 | $8.34 | $8.55 | $8.02 | $8.08 | 10.1M |
| Aug 25, 2026 | $8.16 | $8.48 | $8.0307 | $8.44 | 11.91M |
| Aug 24, 2026 | $8.08 | $8.36 | $7.79 | $8.06 | 15.73M |
| Aug 21, 2026 | $9.08 | $9.30 | $8.145 | $8.29 | 27.81M |
| Aug 20, 2026 | $8.07 | $9.36 | $7.96 | $8.99 | 43.81M |
The latest Smart Investors Daily articles mentioning IOVA.
IOVA research
Company profile and research snapshot.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 20, 2026 | UBS | Neutral | — |
| Aug 18, 2026 | Mizuho | Outperform | — |
| Aug 7, 2026 | Citizens | Market Outperform | — |
| Aug 7, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 15, 2026
Iovance executive Brian Gastman said on Tuesday at a conference that the company’s science was never the hindrance, but getting its therapy to patients.
Yahoo · Sep 4, 2026
SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences: Wells Fargo 21st Annual Healthcare ConferenceFireside Chat: September 10, 2026, at 11:00 a.m. ETBoston, MA H.C. Wainwright 28th Annual Global
Benzinga · Sep 2, 2026
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Yahoo · Aug 27, 2026
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IOVA.
